How effective is lamivudine dolutegravir tablets?

Lamivudine dolutegravir tablets(Dovito)The therapeutic effect is significant. In HIV-1 treatment-experienced adults, switching to lamivudine dolutegravir tablets (DTG/3TC) demonstrated long-term noninferiority compared with continued tenofovir alafenamide-based regimens. Phase 3SALSAstudy evaluated switching to DTG/3TCEffectiveness and safety compared with continued use of current antiretroviral therapies (CARs) with various 3/4 drugs.

Overall, 493 adults (39% were female; 39% were aged ≥50 years; 19%African Americans/African ancestry; 14%Asians) were randomly converted to DTG/3TC(n = 246) or continue with CAR (n = 247). In week 48, DTG/3TC ranked 1 (0.4%) participants and 3 (1.2%) participants in the CAR group’s HIV-1 RNA ≥50copies/mL (snapshot), demonstrating non-inferiority (adjusted difference -0.8% ;95%The confidence interval is-2.4%, 0.8%). Zero participants met confirmed virological withdrawal criteria; therefore, no resistance testing was performed. At week 48, the rate of drug-related adverse events in the DTG/3TC group (20%) was higher than that of CAR group (6%), but the incidence was comparable after week 24 (5% and 2% respectively). DTG/3TCimproves proximal tubular function and bone turnover biomarkers. Changes in blood lipids and inflammatory biomarkers were minimal in both groups. Switching to DTG/3TC was non-inferior to continuing CAR, with maintained virologic suppression and no observed resistance at 48 weeks, supporting DTG/3TC’s efficacy, favorable safety profile, and high resistance barrier. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.